Koers Mabvax Therapeutics Holdings Inc Nasdaq
Aandelen
US55414P7024
Biotechnologie & Medisch Onderzoek
Omzet 2016 | 148K 136K | Omzet 2017 | - | Marktkapitalisatie | 14,41 mln. 13,26 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2016 | -17 mln. -15,64 mln. | Nettowinst (verlies) 2017 | -19 mln. -17,48 mln. | EV/omzet 2016 | 147 x |
Nettoschuld 2016 | 470K 433K | Nettoschuld 2017 | 2,48 mln. 2,28 mln. | EV/omzet 2017 | - |
K/w-verhouding 2016 |
-0,93
x | K/w-verhouding 2017 |
-0,25
x | Werknemers | - |
Dividendrendement 2016 * |
-
| Dividendrendement 2017 |
-
| Vrij verhandelbaar | 92,02% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 72 | - | |
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 | |
Paul W. Maffuid
CTO | Chief Tech/Sci/R&D Officer | 68 | 08-07-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,42% | 115 mld. | |
+11,84% | 106 mld. | |
-1,05% | 21,96 mld. | |
-14,15% | 21,84 mld. | |
-5,29% | 19,21 mld. | |
-4,16% | 18,08 mld. | |
-38,29% | 17,71 mld. | |
+7,99% | 14,32 mld. | |
+36,24% | 12,42 mld. |